Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 7/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525991 | 0.94 | KDM4E (0.36) | ALDH1A1L3MBTL1KDM4ERXFP1PIK3CA | |
| SCHEMBL1170500 | 0.94 | KDM4E (0.36) | ALDH1A1L3MBTL1KDM4ERXFP1PIK3CA | |
| SCHEMBL1169659 | 0.88 | KDM4E (0.36) | ALDH1A1L3MBTL1KDM4ERXFP1PIK3CA | |
| SCHEMBL1169977 | 0.86 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1KDM4ERXFP1PIK3CA | |
| SCHEMBL12864848 | 0.84 | L3MBTL1 (0.35) | ALDH1A1L3MBTL1KDM4ERXFP1ALOX15 | |
| SCHEMBL12778062 | 0.84 | L3MBTL1 (0.39) | ALDH1A1L3MBTL1KDM4ERXFP1PIK3CA | |
| SCHEMBL12777203 | 0.82 | MEN1 (0.45) | ALDH1A1L3MBTL1KDM4EALOX15RAB9A | |
| SCHEMBL14064612 | 0.82 | KDM4E (0.37) | ALDH1A1L3MBTL1KDM4EALOX15RAB9A | |
| SCHEMBL2525820 | 0.80 | MTOR (0.42) | ALDH1A1L3MBTL1KDM4ERXFP1MTOR | |
| SCHEMBL14064643 | 0.80 | KDM4E (0.35) | ALDH1A1L3MBTL1KDM4ERXFP1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2007061714-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111984-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | ALDH1A1 348/4885L3MBTL1 2458/4885KDM4E 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.